Can Bacteriocins Curb the Emergence of Antibiotic Resistant Pathogenic Bacteria in the Globe?

Abstract

The global clinical medicine, on facing the bacterial antibiotic resistance emergence problem, is at the antibiotic invention crisis. The bacterially (good commensal bacteria) formed bacteriocins (which are non-toxic as well as non-immunogenic and bacterial resistance to which is deemed weak), hardly produce adverse effect on the host, and potentially impede and evade the infection with antibiotic resistant pathogenic bacteria (ARPB), in humans. This unlocks an improved vista in developing novel treatment regime utilizing the ‘acquiescent to bioengineering’ bacteriocins to be useful alone in place of antibiotics or in combination with antibiotics.